Brantley et al. [35] provided a rationale for the continued development of AFP464 (Figure 4), which is a precursor of aminoflavone, as an agent to enhance the therapeutic management of breast cancer via dysregulation of the aryl hydrocarbon receptor (AhR) signaling pathway. This evidence concerns the gene AHR and breast carcinoma.